Compare Charles River Laboratories Intl. Inc (CRL) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Li Auto Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Li Auto Inc trades at $12.68 (market cap $12.28B). The key difference: Charles River Laboratories Intl. Inc and Li Auto Inc are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals.
| CRL | LI | |
|---|---|---|
Market Cap | $13.46B | $12.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $282.00 | $26.69 |
52-Week Low | $145.57 | $11.74 |
Enterprise Value | $16.30B | $1.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Li Auto (LI) trades at $12.49, down 2.73% on the day, amid a bearish technical signal and mixed earnings performance. The company reported a net income margin of -1.66% for 2025, with revenue declining to $112.31 billion from $144.5 billion in 2024, while launching new SUV models like the Li L6 in July 2026 to boost deliveries. Analyst consensus is a 'Buy' with a $14.80 price target, but negative cash flow and competitive pressures in China's EV market pose challenges.
Outlook remains cautious due to profitability concerns and volatile cash flows, with near-term risks from domestic competition and global expansion hurdles. The stock offers potential upside if execution improves, but investors should monitor delivery trends and margin recovery amid industry headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
